Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Clinical proteomics in ne… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Clinical proteomics in neurodegenerative disorders.

Forskningsöversiktsartikel
Författare Henrik Zetterberg
Ulla Rüetschi
Erik Portelius
Gunnar Brinkmalm
Ulf Andreasson
Kaj Blennow
Ann Brinkmalm-Westman
Publicerad i Acta neurologica Scandinavica
Volym 118
Nummer/häfte 1
Sidor 1-11
ISSN 1600-0404
Publiceringsår 2008
Publicerad vid Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin
Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 1-11
Språk en
Länkar dx.doi.org/10.1111/j.1600-0404.2007...
Ämnesord Biological Markers, metabolism, Humans, Mass Spectrometry, Neurodegenerative Diseases, diagnosis, genetics, metabolism, Proteomics
Ämneskategorier Neurokemi

Sammanfattning

Neurodegenerative disorders are characterized by neuronal impairment that eventually leads to neuronal death. In spite of the brain's known capacity for regeneration, lost neurons are difficult to replace. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to be most effective if the treatment is initiated as early as possible. However, clinical manifestations in early disease stages are often numerous, subtle and difficult to diagnose. This is where biomarkers that specifically reflect onset of pathology, directly or indirectly, may have a profound impact on diagnosis making in the future. A triplet of biomarkers for Alzheimer's disease (AD), total and hyperphosphorylated tau and the 42 amino acid isoform of beta-amyloid, has already been established for early detection of AD before the onset of dementia. However, more biomarkers are needed both for AD and for other neurodegenerative disorders, such as Parkinson's disease, frontotemporal dementia and amyotrophic lateral sclerosis. This review provides an update on recent advances in clinical neuroproteomics, a biomarker discovery field that has expanded immensely during the last decade, and gives an overview of the most commonly used techniques and the major clinically relevant findings these techniques have lead to.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?